Loading...
XPARGNFT
Market cap180mUSD
Dec 24, Last price  
3.48EUR
1D
0.29%
1Q
-26.95%
Jan 2017
-83.48%
IPO
-72.40%
Name

Genfit SA

Chart & Performance

D1W1MN
XPAR:GNFT chart
P/E
—
P/S
6.07
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
9.78%
Rev. gr., 5y
233.73%
Revenues
29m
+41.45%
12,774,60010,051,9009,477,3008,760,6005,812,2003,757,5002,360,9001,672,3001,899,3001,614,400527,000284,000118,00069,00030,839,000765,00080,069,00020,195,00028,565,000
Net income
-29m
L+21.81%
1,773,100327,700-2,800,800-3,960,500-7,373,900-9,380,600-9,681,700-5,411,600-12,652,100-17,025,500-17,135,000-33,667,000-58,604,000-79,521,000-65,145,000-101,221,00067,259,000-23,720,000-28,894,000
CFO
-55m
L-23.69%
1,675,500-1,743,400-4,814,000-5,162,800-221,000-5,393,800-7,113,700-7,861,900-9,191,200-15,491,400-14,870,000-27,226,000-49,856,000-56,081,000-47,680,000-96,371,00099,915,000-72,638,000-55,429,000
Earnings
Apr 02, 2025

Profile

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
URL
https://www.genfit.fr/
IPO date
Dec 19, 2006
Employees
148
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
28,565
41.45%
20,195
-74.78%
80,069
10,366.54%
Cost of revenue
55,092
53,463
53,019
Unusual Expense (Income)
NOPBT
(26,527)
(33,268)
27,050
NOPBT Margin
33.78%
Operating Taxes
380
(116)
2,215
Tax Rate
8.19%
NOPAT
(26,907)
(33,152)
24,835
Net income
(28,894)
21.81%
(23,720)
-135.27%
67,259
-166.45%
Dividends
Dividend yield
Proceeds from repurchase of equity
5
27,972
BB yield
0.00%
-11.65%
Debt
Debt current
7,926
5,080
2,188
Long-term debt
68,137
76,754
79,116
Deferred revenue
9,706
25,821
Other long-term liabilities
5,188
1,231
1,316
Net debt
(4,545)
(63,631)
(181,883)
Cash flow
Cash from operating activities
(55,429)
(72,638)
99,915
CAPEX
(414)
(537)
Cash from investing activities
2,234
(46,266)
(3,377)
Cash from financing activities
(5,098)
(3,786)
(8,916)
FCF
(31,364)
(32,347)
27,468
Balance
Cash
77,789
140,551
258,756
Long term investments
2,819
4,914
4,431
Excess cash
79,180
144,455
259,184
Stockholders' equity
(376,339)
(350,154)
(325,341)
Invested Capital
519,657
525,988
540,759
ROIC
4.49%
ROCE
12.52%
EV
Common stock shares outstanding
49,700
49,674
55,614
Price
3.54
-10.79%
3.97
-8.06%
4.32
8.12%
Market cap
175,939
-10.74%
197,106
-17.88%
240,028
54.73%
EV
171,394
133,475
58,145
EBITDA
(24,873)
(31,436)
29,792
EV/EBITDA
1.95
Interest
4,624
4,758
7,122
Interest/NOPBT
26.33%